SenesTech (SNES) 10-Q 10 Aug 23 2023 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2023	Aug. 09, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity File Number	001-37941
Entity Registrant Name	SENESTECH, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-2079805
Entity Address, Address Line One	23460 N 19th Ave,
Entity Address, Address Line Two	Suite 110
Entity Address, City or Town	Phoenix
Entity Address, State or Province	AZ
Entity Address, Postal Zip Code	85027
City Area Code	(928)
Local Phone Number	779-4143
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	SNES
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		2,964,485
Entity Central Index Key	0001680378
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Amendment Flag	false

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 2,196	$ 4,775
Accounts receivable, net	44	113
Prepaid expenses	330	378
Inventory, net	765	853
Total current assets	3,335	6,119
Right to use assets, operating leases	261	347
Property and equipment, net	245	294
Other noncurrent assets	22	22
Total assets	3,863	6,782
Current liabilities:
Accounts payable	120	540
Accrued expenses	621	560
Current portion of operating lease liability	188	180
Deferred revenue	24	44
Total current liabilities	953	1,324
Operating lease liability, less current portion	83	179
Total liabilities	1,036	1,503
Commitments and contingencies (see notes)
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding	0	0
Common stock, $0.001 par value, 100,000,000 shares authorized, 2,964,485 and 809,648 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively	3	1
Additional paid-in capital	129,057	127,481
Accumulated deficit	(126,233)	(122,203)
Total stockholders’ equity	2,827	5,279
Total liabilities and stockholders’ equity	$ 3,863	$ 6,782

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	2,964,485	809,648
Common stock, shares outstanding (in shares)	2,964,485	809,648

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Revenues, net	$ 305	$ 277	$ 538	$ 472
Cost of sales	163	141	304	246
Gross profit	142	136	234	226
Operating expenses:
Research and development	381	431	768	947
Selling, general and administrative	1,761	2,277	3,511	4,184
Total operating expenses	2,142	2,708	4,279	5,131
Loss from operations	(2,000)	(2,572)	(4,045)	(4,905)
Other income (expense):
Interest income	7	1	15	3
Interest expense	0	0	0	(1)
Miscellaneous income	0	2	0	2
Other income, net	7	3	15	4
Net loss	(1,993)	(2,569)	(4,030)	(4,901)
Comprehensive loss	$ (1,993)	$ (2,569)	$ (4,030)	$ (4,901)
Weighted average shares outstanding - basic (in shares)	2,860,874	610,635	2,208,162	610,543
Weighted average shares outstanding - diluted (in shares)	2,860,874	610,635	2,208,162	610,543
Net loss per share - basic (in dollars per share)	$ (0.70)	$ (4.21)	$ (1.83)	$ (8.03)
Net loss per share - diluted (in dollars per share)	$ (0.70)	$ (4.21)	$ (1.83)	$ (8.03)

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net loss	$ (4,030)	$ (4,901)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	69	113
Stock-based compensation	336	430
Bad debt expense	(2)	12
Changes in operating assets and liabilities:
Accounts receivable	71	(19)
Other assets	(2)	0
Prepaid expenses	92	(108)
Inventory	88	25
Accounts payable	(420)	(47)
Accrued expenses	61	306
Deferred revenue	(20)	41
Net cash used in operating activities	(3,757)	(4,148)
Cash flows from investing activities:
Purchase of property and equipment	(21)	(146)
Net cash used in investing activities	(21)	(146)
Cash flows from financing activities:
Proceeds from the issuance of common stock, net	1,210	0
Repayments of notes payable	0	(5)
Repayments of finance lease obligations	0	(27)
Payment of employee withholding taxes related to share based awards	(11)	0
Net cash provided by (used in) financing activities	1,199	(32)
Decrease in cash and cash equivalents	(2,579)	(4,326)
Cash and cash equivalents, beginning of period	4,775	9,326
Cash and cash equivalents, end of period	2,196	5,000
Supplemental disclosures of cash flow information:
Interest paid	0	1
Income taxes paid	$ 0	$ 0

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION Nature of Business SenesTech, Inc. (subsequently referred to in this report as “we,” “us,” “our,” or “our Company”) was incorporated in the state of Nevada in July 2004. On November 12, 2015, we subsequently reincorporated in the state of Delaware. Our corporate headquarters and manufacturing site are in Phoenix, Arizona. We have developed and are commercializing a global, proprietary technology for managing animal pest populations, initially rat populations, through fertility control with our product known as ContraPest ® . ContraPest is a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide and triptolide. ContraPest limits reproduction of male and female rats beginning with the first breeding cycle following consumption. ContraPest is being marketed for use in controlling Norway and roof rat populations. In addition to the U.S. Environmental Protection Agency registration of ContraPest, we must obtain registration from the various state regulatory agencies prior to selling in each state. To date, we have received registration for ContraPest in all 50 states and the District of Columbia, 49 of which have approved the removal of the Restricted Use designation, as well as the District of Columbia and five major U.S. territories. Going Concern Our condensed financial statements as of June 30, 2023 were prepared under the assumption that we would continue as a going concern. The reports of our independent registered public accounting firm that accompanies our financial statements for each of the years ended December 31, 2022 and December 31, 2021 contain a going concern qualification in which such firm expressed substantial doubt about our ability to continue as a going concern, based on the financial statements at that time. Specifically, we have incurred operating losses since our inception, and we expect to continue to incur significant expenses and operating losses for the foreseeable future. These prior losses and expected future losses have had, and will continue to have, an adverse effect on our financial condition. If we encounter continued issues or delays in the commercialization of ContraPest, our expected future losses could have an adverse effect on our financial condition and negatively impact our ability to fund continued operations, obtain additional financing in the future and continue as a going concern. There are no assurances that such financing, if necessary, will be available to us at all or will be available in sufficient amounts or on reasonable terms. Our financial statements do not include any adjustments that may result from the outcome of this uncertainty. If we are unable to generate additional funds in the future through additional financings, sales of our products, licensing fees, royalty payments or from other sources or transactions, we will exhaust our resources and will be unable to continue operations. Liquidity and Capital Resources Since our inception, we have sustained significant operating losses in the course of our research and development and commercialization activities and expect such losses to continue for the near future. We have generated limited revenue to date from product sales, research grants and licensing fees received under a former license agreement. We have primarily funded our operations to date through the sale of equity securities, including convertible preferred stock, common stock and warrants to purchase common stock. We have also raised capital through debt financing, consisting primarily of convertible notes and government loan programs, and, to a lesser extent, payments received in connection with product sales, research grants and licensing fees. As of June 30, 2023, we had an accumulated deficit of $126.2 million and cash and cash equivalents of $2.2 million. Our ultimate success depends upon the outcome of a combination of factors, including the following: (i) successful commercialization of ContraPest and maintaining and obtaining regulatory approval of our products and product candidates; (ii) market acceptance, commercial viability and profitability of ContraPest and other products; (iii) the ability to market our products and establish an effective sales force and marketing infrastructure to generate significant revenue; (iv) the success of our research and development; (v) the ability to retain and attract key personnel to develop, operate and grow our business; and (vi) our ability to meet our working capital needs. Based upon our current operating plan, we expect that cash and cash equivalents at June 30, 2023, in combination with anticipated revenue and any additional sales of our equity securities (see Note 10), will be sufficient to fund our current operations for at least the next three months. While we have evaluated and continue to evaluate our operating expenses and concentrate our resources toward the successful commercialization of ContraPest in the United States, additional financing will be needed before achieving anticipated revenue targets and margin targets. If we are unable to raise necessary capital through the sale of our securities, we may be required to take other measures that could impair our ability to be successful and operate as a going concern. In any event, additional capital is needed in order to fund our operating losses and research and development activities before we become profitable. We may never achieve profitability or generate positive cash flows, and unless and until we do, we will continue to need to raise capital through equity or debt financing. If such equity or debt financing is not available at adequate levels or on acceptable terms, we may need to delay, limit or terminate commercialization and development efforts or discontinue operations. Condensed Financial Statements Our accompanying unaudited condensed financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with the U.S. generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. In our opinion, the unaudited condensed financial statements include all material adjustments, all of which are of a normal and recurring nature, necessary to present fairly our financial position as of June 30, 2023, and our operating results and cash flows for the three- and six-month periods ended June 30, 2023 and 2022. The accompanying financial information as of December 31, 2022 is derived from audited financial statements. Interim results are not necessarily indicative of results for a full year. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 17, 2023. Recent Accounting Pronouncements There have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, to our condensed financial statements. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and classification of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The significant estimates in our financial statements include the valuation of inventory, common stock warrants, and stock-based awards, such as stock options and restricted stock units. Actual results could differ from such estimates. Comprehensive Loss We have no other comprehensive income items for the periods presented. As a result, our net loss and comprehensive loss were the same for the periods presented and a separate statement of comprehensive loss is not included in the accompanying condensed financial statements.

BALANCE SHEET COMPONENTS

BALANCE SHEET COMPONENTS	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BALANCE SHEET COMPONENTS	BALANCE SHEET COMPONENTS Cash and Cash Equivalents Highly liquid investments with maturities of three months or less as of the date of acquisition are classified as cash equivalents, of which we had $2.2 million and $4.8 million as of June 30, 2023 and December 31, 2022, respectively, included within cash and cash equivalents in the condensed balance sheets. Accounts Receivable, Net Accounts receivable, net consisted of the following (in thousands): June 30, December 31, Accounts receivable $ 48 $ 119 Allowance for uncollectible accounts (4) (6) Accounts receivable, net $ 44 $ 113 The following was the activity in the allowance for uncollectible accounts (in thousands): Three Months Ended Six Months Ended 2023 2022 2023 2022 Balance as of beginning of period $ 4 $ — $ 6 $ — Increase in provision — 12 — 12 Amounts written off, less recoveries — — (2) — Balance as of end of period $ 4 $ 12 $ 4 $ 12 Inventory, net Inventory, net consisted of the following (in thousands): June 30, December 31, Raw materials $ 729 $ 772 Finished goods 54 99 Total inventory 783 871 Less: reserve for obsolescence (18) (18) Inventory, net $ 765 $ 853 The following was the activity in the reserve for obsolescence (in thousands): Three Months Ended Six Months Ended 2023 2022 2023 2022 Balance as of beginning of period $ 18 $ 26 $ 18 $ 29 Increase in reserve — — — — Amounts relieved — (4) — (7) Balance as of end of period $ 18 $ 22 $ 18 $ 22 Prepaid Expenses Prepaid expenses consisted of the following (in thousands): June 30, December 31, Professional services $ 107 $ 41 Insurance 97 61 Software licenses 94 157 Other 14 6 Patents 10 39 Marketing programs and conferences 8 74 Total prepaid expenses $ 330 $ 378 Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): June 30, December 31, Research and development equipment $ 1,569 $ 1,558 Office and computer equipment 803 800 Autos 54 54 Furniture and fixtures 41 41 Leasehold improvements 119 119 Total in service 2,586 2,572 Accumulated depreciation and amortization (2,353) (2,283) Total in service, net 233 289 Construction in progress 12 5 Property and equipment, net $ 245 $ 294 Accrued Expenses Accrued expenses consisted of the following (in thousands): June 30, December 31, Compensation, severance and related benefits $ 468 $ 497 Legal services 138 36 Product warranty 15 18 Personal property and franchise tax — 6 Other — 3 Total accrued expenses $ 621 $ 560

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTSThe carrying amounts of our financial instruments, including accounts payable and accrued liabilities, approximate fair value due to their short maturities.

LEASES

LEASES	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
LEASES	LEASES We have operating leases for our corporate headquarters and our manufacturing and research facility, which expire in 2024. We were obligated under finance leases for certain research and computer equipment, of which the last arrangement expired in June 2022. The components of lease cost were as follows (in thousands): Three Months Ended Six Months Ended 2023 2022 2023 2022 Operating lease cost $ 55 $ 56 $ 111 $ 112 Finance lease cost: Amortization of right-of-use asset $ — $ 11 $ — $ 27 Interest on lease liability — — — 1 Total finance lease cost $ — $ 11 $ — $ 28 As of June 30, 2023, maturities of operating lease liabilities were follows (in thousands): 2023 $ 99 2024 186 Total operating lease payments 285 Less imputed interest (14) Total operating lease liabilities $ 271
LEASES	LEASES We have operating leases for our corporate headquarters and our manufacturing and research facility, which expire in 2024. We were obligated under finance leases for certain research and computer equipment, of which the last arrangement expired in June 2022. The components of lease cost were as follows (in thousands): Three Months Ended Six Months Ended 2023 2022 2023 2022 Operating lease cost $ 55 $ 56 $ 111 $ 112 Finance lease cost: Amortization of right-of-use asset $ — $ 11 $ — $ 27 Interest on lease liability — — — 1 Total finance lease cost $ — $ 11 $ — $ 28 As of June 30, 2023, maturities of operating lease liabilities were follows (in thousands): 2023 $ 99 2024 186 Total operating lease payments 285 Less imputed interest (14) Total operating lease liabilities $ 271

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION In 2018, our stockholders approved the adoption of the SenesTech, Inc. 2018 Equity Incentive Plan (the “2018 Plan”). The 2018 Plan has since been amended and restated on certain occasions, most recently on June 26, 2023, when our stockholders approved an increase to the total number of authorized shares to 848,614 shares. Stock options are generally issued with a per share exercise price equal to the fair market value of our common stock at the date of grant. Options granted generally vest immediately, or ratably over a 12- to 36-month period coinciding with their respective service periods, with terms generally of five years. Certain stock option awards provide for accelerated vesting upon a change in control. As of June 30, 2023, we had 465,580 shares of common stock available for issuance under the 2018 Plan. Stock Options The following table presents the outstanding stock option activity: Number of Options Weighted Weighted Three months ended June 30, 2023: Outstanding as of March 31, 2023 280,448 $ 17.11 4.4 Granted 199,421 1.25 5.0 Exercised — — — Forfeited (107) 39.64 — Expired (336) 118.25 — Outstanding as of June 30, 2023 479,426 (1) 10.01 4.5 Six months ended June 30, 2023: Outstanding as of December 31, 2022 280,810 17.00 3.9 Granted 199,421 1.25 5.0 Exercised — — — Forfeited (433) 119.46 — Expired (372) 680.87 — Outstanding as of June 30, 2023 479,426 (1) 10.01 4.5 Exercisable as of June 30, 2023 139,583 29.16 3.8 (1) Includes options related to 99,000 shares that are inducement awards and not granted under the 2018 Plan. The weighted average grant date fair value of options granted during the six months ended June 30, 2023 was $1.24 per share, based on the following assumptions used in the Black-Scholes option pricing model: Expected volatility 128 % Expected dividend yield — Expected term (in years) 5 Risk-free interest rate 5.3 % The expected volatility assumption is based on the calculated volatility of our common stock at the date of grant based on historical prices over the most recent period commensurate with the term of the award. The expected dividend yield assumption is based on our history and expected dividend payouts: we have not, and do not expect to, pay dividends. The expected term assumption is the contractual term of the options for non-employees. The risk-free interest rate assumption is determined using the U.S. treasury yields for bonds with a maturity commensurate with the term of the award. Restricted Stock Units The following table presents the unvested restricted stock unit activity: Number of Weighted Unvested balance as of December 31, 2022 18,799 $ 2.71 Granted — — Vested (18,799) 2.71 Forfeited — — Unvested balance as of June 30, 2023 — — The stock-based compensation expense was recorded as follows (in thousands): Three Months Ended Six Months Ended 2023 2022 2023 2022 Research and development $ 5 $ 3 $ 9 $ 4 Selling, general and administrative (1) 165 203 327 426 Total stock-based compensation expense $ 170 $ 206 $ 336 $ 430 (1) For the three and six month periods ended June 30, 2023, includes $56,000 related to stock issued in exchange for marketing services. The allocation between research and development and selling, general and administrative expense was based on the department and services performed by the employee or non-employee. At June 30, 2023, the total compensation cost related to unvested options not yet recognized was $469,000, which will be recognized over a weighted average period of 1.6 years, assuming the employees and non-employees complete their service period required for vesting.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY Activity in equity during the six month periods ended June 30, 2023 and 2022 was as follows (dollars in thousands): Common Stock Additional Accumulated Total Shares Amount 2023 Balances as of December 31, 2022 809,648 $ 1 $ 127,481 $ (122,203) $ 5,279 Stock-based compensation — — 166 — 166 Issuance of common stock upon exercise of warrants 1,230,000 1 (1) — — Issuance of common stock for service 54,466 — 100 — 100 Issuance of shares pursuant to the vesting of restricted stock units, net of shares withheld for taxes 13,225 — (11) — (11) Net loss — — — (2,037) (2,037) Balances as of March 31, 2023 2,107,339 2 127,735 (124,240) 3,497 Stock-based compensation — — 113 — 113 Issuance of common stock, net of issuance costs 857,146 1 1,209 — 1,210 Net loss — — — (1,993) (1,993) Balances as of June 30, 2023 2,964,485 $ 3 $ 129,057 $ (126,233) $ 2,827 2022 Balances as of December 31, 2021 610,364 $ 1 $ 122,542 $ (112,508) $ 10,035 Stock-based compensation — — 221 — 221 Issuance of common stock for service 250 — 3 — 3 Net loss — — — (2,332) (2,332) Balances as of March 31, 2022 610,614 1 122,766 (114,840) 7,927 Stock-based compensation — — 205 — 205 Issuance of common stock for service 34 — 1 — 1 Net loss — — — (2,569) (2,569) Balances as of June 30, 2022 610,648 $ 1 $ 122,972 $ (117,409) $ 5,564 During the six months ended June 30, 2023, the following shares of common stock were issued: • 857,146 shares pursuant to a registered direct offering with certain institutional investors for $1.75 per share for gross proceeds of $1.5 million, before deducting issuance costs of $290,000. The shares were offered and sold pursuant to a prospectus, dated May 6, 2022, and a prospectus supplement, dated April 10, 2023, in connection with a takedown from our shelf registration statement on Form S-3 (File No. 333-261227). • 1,230,000 shares pursuant to the exercise of previously outstanding prefunded warrants, which were issued in November 2022 with an exercise price of $3.50 per share; • 54,466 restricted shares in exchange for marketing services to be performed through September 2023, with the total value of services to be recognized based on the stock price on the date of issuance; and • 13,225 shares pursuant to the vesting of restricted stock units. The following table presents the common stock warrant activity: Shares Weighted Weighted Outstanding as of December 31, 2022 4,414,810 $ 6.58 3.0 Issued 921,432 1.66 5.3 Exercised (1,230,000) 3.50 — Expired (2,835) 728.00 — Outstanding as of June 30, 2023 4,103,407 5.91 3.2 During the six months ended June 30, 2023: • Series C warrants were issued to the investors in the offering discussed in Note 6 to purchase up to 857,146 shares of our common stock. The Series C warrants are exercisable immediately with an exercise price of $1.62 per share and expire October 12, 2028. We estimated the fair value of these warrants to be $1.1 million using a Black-Scholes model based on the following significant inputs: common stock price of $1.38 per share; volatility of 164%; term of 5.5 years; dividend yield of —%; and risk-free interest rate of 3.4%; • Placement agent warrants were issued to purchase up to 64,286 shares of our common stock. The placement agent warrants are exercisable immediately upon issuance, with an exercise price per share of $2.1875 per share, and expire April 10, 2028. We estimated the fair value of these warrants to be $82,000 using a Black-Scholes model based on the following significant inputs: common stock price of $1.38 per share; volatility of 165%; term of 5 years; dividend yield of —%;and risk-free interest rate of 3.5%; and • Prefunded warrants representing 1,230,000 shares of common stock were exercised. Such prefunded warrants were issued in November 2022 with an exercise price of $3.50 per share.

COMMON STOCK WARRANTS

COMMON STOCK WARRANTS	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
COMMON STOCK WARRANTS	STOCKHOLDERS’ EQUITY Activity in equity during the six month periods ended June 30, 2023 and 2022 was as follows (dollars in thousands): Common Stock Additional Accumulated Total Shares Amount 2023 Balances as of December 31, 2022 809,648 $ 1 $ 127,481 $ (122,203) $ 5,279 Stock-based compensation — — 166 — 166 Issuance of common stock upon exercise of warrants 1,230,000 1 (1) — — Issuance of common stock for service 54,466 — 100 — 100 Issuance of shares pursuant to the vesting of restricted stock units, net of shares withheld for taxes 13,225 — (11) — (11) Net loss — — — (2,037) (2,037) Balances as of March 31, 2023 2,107,339 2 127,735 (124,240) 3,497 Stock-based compensation — — 113 — 113 Issuance of common stock, net of issuance costs 857,146 1 1,209 — 1,210 Net loss — — — (1,993) (1,993) Balances as of June 30, 2023 2,964,485 $ 3 $ 129,057 $ (126,233) $ 2,827 2022 Balances as of December 31, 2021 610,364 $ 1 $ 122,542 $ (112,508) $ 10,035 Stock-based compensation — — 221 — 221 Issuance of common stock for service 250 — 3 — 3 Net loss — — — (2,332) (2,332) Balances as of March 31, 2022 610,614 1 122,766 (114,840) 7,927 Stock-based compensation — — 205 — 205 Issuance of common stock for service 34 — 1 — 1 Net loss — — — (2,569) (2,569) Balances as of June 30, 2022 610,648 $ 1 $ 122,972 $ (117,409) $ 5,564 During the six months ended June 30, 2023, the following shares of common stock were issued: • 857,146 shares pursuant to a registered direct offering with certain institutional investors for $1.75 per share for gross proceeds of $1.5 million, before deducting issuance costs of $290,000. The shares were offered and sold pursuant to a prospectus, dated May 6, 2022, and a prospectus supplement, dated April 10, 2023, in connection with a takedown from our shelf registration statement on Form S-3 (File No. 333-261227). • 1,230,000 shares pursuant to the exercise of previously outstanding prefunded warrants, which were issued in November 2022 with an exercise price of $3.50 per share; • 54,466 restricted shares in exchange for marketing services to be performed through September 2023, with the total value of services to be recognized based on the stock price on the date of issuance; and • 13,225 shares pursuant to the vesting of restricted stock units. The following table presents the common stock warrant activity: Shares Weighted Weighted Outstanding as of December 31, 2022 4,414,810 $ 6.58 3.0 Issued 921,432 1.66 5.3 Exercised (1,230,000) 3.50 — Expired (2,835) 728.00 — Outstanding as of June 30, 2023 4,103,407 5.91 3.2 During the six months ended June 30, 2023: • Series C warrants were issued to the investors in the offering discussed in Note 6 to purchase up to 857,146 shares of our common stock. The Series C warrants are exercisable immediately with an exercise price of $1.62 per share and expire October 12, 2028. We estimated the fair value of these warrants to be $1.1 million using a Black-Scholes model based on the following significant inputs: common stock price of $1.38 per share; volatility of 164%; term of 5.5 years; dividend yield of —%; and risk-free interest rate of 3.4%; • Placement agent warrants were issued to purchase up to 64,286 shares of our common stock. The placement agent warrants are exercisable immediately upon issuance, with an exercise price per share of $2.1875 per share, and expire April 10, 2028. We estimated the fair value of these warrants to be $82,000 using a Black-Scholes model based on the following significant inputs: common stock price of $1.38 per share; volatility of 165%; term of 5 years; dividend yield of —%;and risk-free interest rate of 3.5%; and • Prefunded warrants representing 1,230,000 shares of common stock were exercised. Such prefunded warrants were issued in November 2022 with an exercise price of $3.50 per share.

LOSS PER SHARE

LOSS PER SHARE	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
LOSS PER SHARE	LOSS PER SHARE Basic loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares and potentially dilutive securities outstanding during the period determined using the treasury stock method. Stock options, warrants and restricted stock units are considered to be potentially dilutive securities but have been excluded from the calculation of diluted loss per share because their effect would be anti-dilutive given the net losses reported for all periods presented. Therefore, basic and diluted loss per share are the same for each period presented. The following shares were excluded from the calculation of diluted net loss per share: Three Months Ended Six Months Ended 2023 2022 2023 2022 Common stock warrants — — 166,661 — Stock options 10,171 — 75,466 — Restricted stock units — — — — 10,171 — 242,127 —

CONTINGENCIES

CONTINGENCIES	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
CONTINGENCIES	CONTINGENCIES Legal Proceedings In July 2020, our former corporate general counsel (the “Plaintiff”) commenced an action against us in the Superior Court of the State of California, for the County of San Diego. The complaint alleges, among other things, that we breached the Plaintiff’s employment contract with us, as well as the implied covenant of good faith and fair dealing, by refusing to issue him the balance of stock options he claims we owe him. In September 2021, the Plaintiff served us and also named 10 individuals as defendants, consisting of current and former directors and employees. We do not believe that all of the defendants have yet been served. Furthermore, two individually named defendants have separately settled with the Plaintiff. The Plaintiff alleges that such individuals agreed to knowingly and wrongfully withhold the stock options owed to him and are knowingly in receipt of stolen property. The Plaintiff seeks compensatory damages in excess of $500,000, treble damages, and reasonable attorneys’ fees. We do not believe the claims described above have merit and intend to aggressively defend against these accusations. The Plaintiff has agreed to mediation to resolve the issues. We do not believe that this litigation is likely to have a material effect on our operations.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS On July 21, 2023, subject to stockholder approval, our board of directors approved an amendment to our amended and restated certificate of incorporation, as amended, to effect a reverse stock split (the “Reverse Stock Split”) of our issued and outstanding common stock by a ratio of not less than 1-for-2 and not more than 1-for-12. The exact ratio of the Reverse Stock Split will be set within this range as determined by our board of directors in its sole discretion prior to the time of the Reverse Stock Split and will be publicly announced by us prior to the effective time. A special meeting of stockholders is scheduled for August 18, 2023 to vote on such matter, among other items. On July 21, 2023, our board of directors approved a public offering of shares of our common stock, together with Series D and Series E warrants to purchase shares of our common stock for aggregate gross proceeds of up to $7.5 million. See Form S-1 filed with the SEC on July 21, 2023 (File No. 333-273370). We have evaluated subsequent events from the balance sheet date through August 10, 2023, the date at which the condensed financial statements were issued, and determined that there were no additional items that require adjustment to or disclosure in the condensed financial statements.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Pay vs Performance Disclosure
Net loss	$ (1,993)	$ (2,037)	$ (2,569)	$ (2,332)	$ (4,030)	$ (4,901)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Financial Statements	Condensed Financial StatementsOur accompanying unaudited condensed financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with the U.S. generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. In our opinion, the unaudited condensed financial statements include all material adjustments, all of which are of a normal and recurring nature, necessary to present fairly our financial position as of June 30, 2023, and our operating results and cash flows for the three- and six-month periods ended June 30, 2023 and 2022.
Recent Accounting Pronouncements	Recent Accounting Pronouncements There have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, to our condensed financial statements.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and classification of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The significant estimates in our financial statements include the valuation of inventory, common stock warrants, and stock-based awards, such as stock options and restricted stock units. Actual results could differ from such estimates.
Comprehensive Loss	Comprehensive Loss We have no other comprehensive income items for the periods presented. As a result, our net loss and comprehensive loss were the same for the periods presented and a separate statement of comprehensive loss is not included in the accompanying condensed financial statements.
Cash and Cash Equivalents	Cash and Cash Equivalents Highly liquid investments with maturities of three months or less as of the date of acquisition are classified as cash equivalents, of which we had $2.2 million and $4.8 million as of June 30, 2023 and December 31, 2022, respectively, included within cash and cash equivalents in the condensed balance sheets.

BALANCE SHEET COMPONENTS (Table

BALANCE SHEET COMPONENTS (Tables)	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of accounts receivable, net and activity in allowance for uncollectible accounts	Accounts receivable, net consisted of the following (in thousands): June 30, December 31, Accounts receivable $ 48 $ 119 Allowance for uncollectible accounts (4) (6) Accounts receivable, net $ 44 $ 113 The following was the activity in the allowance for uncollectible accounts (in thousands): Three Months Ended Six Months Ended 2023 2022 2023 2022 Balance as of beginning of period $ 4 $ — $ 6 $ — Increase in provision — 12 — 12 Amounts written off, less recoveries — — (2) — Balance as of end of period $ 4 $ 12 $ 4 $ 12
Schedule of inventory, net and activity in reserve for obsolescence	Inventory, net consisted of the following (in thousands): June 30, December 31, Raw materials $ 729 $ 772 Finished goods 54 99 Total inventory 783 871 Less: reserve for obsolescence (18) (18) Inventory, net $ 765 $ 853 The following was the activity in the reserve for obsolescence (in thousands): Three Months Ended Six Months Ended 2023 2022 2023 2022 Balance as of beginning of period $ 18 $ 26 $ 18 $ 29 Increase in reserve — — — — Amounts relieved — (4) — (7) Balance as of end of period $ 18 $ 22 $ 18 $ 22
Schedule of prepaid expenses	Prepaid expenses consisted of the following (in thousands): June 30, December 31, Professional services $ 107 $ 41 Insurance 97 61 Software licenses 94 157 Other 14 6 Patents 10 39 Marketing programs and conferences 8 74 Total prepaid expenses $ 330 $ 378
Schedule of property and equipment, net	Property and equipment, net consisted of the following (in thousands): June 30, December 31, Research and development equipment $ 1,569 $ 1,558 Office and computer equipment 803 800 Autos 54 54 Furniture and fixtures 41 41 Leasehold improvements 119 119 Total in service 2,586 2,572 Accumulated depreciation and amortization (2,353) (2,283) Total in service, net 233 289 Construction in progress 12 5 Property and equipment, net $ 245 $ 294
Schedule of accrued expenses	Accrued expenses consisted of the following (in thousands): June 30, December 31, Compensation, severance and related benefits $ 468 $ 497 Legal services 138 36 Product warranty 15 18 Personal property and franchise tax — 6 Other — 3 Total accrued expenses $ 621 $ 560

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Schedule of components of lease cost	The components of lease cost were as follows (in thousands): Three Months Ended Six Months Ended 2023 2022 2023 2022 Operating lease cost $ 55 $ 56 $ 111 $ 112 Finance lease cost: Amortization of right-of-use asset $ — $ 11 $ — $ 27 Interest on lease liability — — — 1 Total finance lease cost $ — $ 11 $ — $ 28
Schedule of future minimum operating lease payments	As of June 30, 2023, maturities of operating lease liabilities were follows (in thousands): 2023 $ 99 2024 186 Total operating lease payments 285 Less imputed interest (14) Total operating lease liabilities $ 271

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of stock option activity	The following table presents the outstanding stock option activity: Number of Options Weighted Weighted Three months ended June 30, 2023: Outstanding as of March 31, 2023 280,448 $ 17.11 4.4 Granted 199,421 1.25 5.0 Exercised — — — Forfeited (107) 39.64 — Expired (336) 118.25 — Outstanding as of June 30, 2023 479,426 (1) 10.01 4.5 Six months ended June 30, 2023: Outstanding as of December 31, 2022 280,810 17.00 3.9 Granted 199,421 1.25 5.0 Exercised — — — Forfeited (433) 119.46 — Expired (372) 680.87 — Outstanding as of June 30, 2023 479,426 (1) 10.01 4.5 Exercisable as of June 30, 2023 139,583 29.16 3.8 (1) Includes options related to 99,000 shares that are inducement awards and not granted under the 2018 Plan.
Schedule of fair value of options granted, assumptions	The weighted average grant date fair value of options granted during the six months ended June 30, 2023 was $1.24 per share, based on the following assumptions used in the Black-Scholes option pricing model: Expected volatility 128 % Expected dividend yield — Expected term (in years) 5 Risk-free interest rate 5.3 %
Schedule of restricted stock unit activity	The following table presents the unvested restricted stock unit activity: Number of Weighted Unvested balance as of December 31, 2022 18,799 $ 2.71 Granted — — Vested (18,799) 2.71 Forfeited — — Unvested balance as of June 30, 2023 — —
Schedule of stock-based compensation expense	The stock-based compensation expense was recorded as follows (in thousands): Three Months Ended Six Months Ended 2023 2022 2023 2022 Research and development $ 5 $ 3 $ 9 $ 4 Selling, general and administrative (1) 165 203 327 426 Total stock-based compensation expense $ 170 $ 206 $ 336 $ 430 (1) For the three and six month periods ended June 30, 2023, includes $56,000 related to stock issued in exchange for marketing services.

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Schedule of stockholders' equity activity	Activity in equity during the six month periods ended June 30, 2023 and 2022 was as follows (dollars in thousands): Common Stock Additional Accumulated Total Shares Amount 2023 Balances as of December 31, 2022 809,648 $ 1 $ 127,481 $ (122,203) $ 5,279 Stock-based compensation — — 166 — 166 Issuance of common stock upon exercise of warrants 1,230,000 1 (1) — — Issuance of common stock for service 54,466 — 100 — 100 Issuance of shares pursuant to the vesting of restricted stock units, net of shares withheld for taxes 13,225 — (11) — (11) Net loss — — — (2,037) (2,037) Balances as of March 31, 2023 2,107,339 2 127,735 (124,240) 3,497 Stock-based compensation — — 113 — 113 Issuance of common stock, net of issuance costs 857,146 1 1,209 — 1,210 Net loss — — — (1,993) (1,993) Balances as of June 30, 2023 2,964,485 $ 3 $ 129,057 $ (126,233) $ 2,827 2022 Balances as of December 31, 2021 610,364 $ 1 $ 122,542 $ (112,508) $ 10,035 Stock-based compensation — — 221 — 221 Issuance of common stock for service 250 — 3 — 3 Net loss — — — (2,332) (2,332) Balances as of March 31, 2022 610,614 1 122,766 (114,840) 7,927 Stock-based compensation — — 205 — 205 Issuance of common stock for service 34 — 1 — 1 Net loss — — — (2,569) (2,569) Balances as of June 30, 2022 610,648 $ 1 $ 122,972 $ (117,409) $ 5,564

COMMON STOCK WARRANTS (Tables)

COMMON STOCK WARRANTS (Tables)	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Schedule of common stock warrant activity	The following table presents the common stock warrant activity: Shares Weighted Weighted Outstanding as of December 31, 2022 4,414,810 $ 6.58 3.0 Issued 921,432 1.66 5.3 Exercised (1,230,000) 3.50 — Expired (2,835) 728.00 — Outstanding as of June 30, 2023 4,103,407 5.91 3.2

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Schedule of outstanding potentially dilutive securities	The following shares were excluded from the calculation of diluted net loss per share: Three Months Ended Six Months Ended 2023 2022 2023 2022 Common stock warrants — — 166,661 — Stock options 10,171 — 75,466 — Restricted stock units — — — — 10,171 — 242,127 —

BASIS OF PRESENTATION (Details)

BASIS OF PRESENTATION (Details) $ in Thousands	Jun. 30, 2023 USD ($) state territory	Dec. 31, 2022 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of states registration received | state	50
Number of states approved removal of RUP designation | state	49
Number of major U.S. territories registration received | territory	5
Accumulated deficit | $	$ 126,233	$ 122,203
Cash and cash equivalents | $	$ 2,196	$ 4,775

BALANCE SHEET COMPONENTS - Narr

BALANCE SHEET COMPONENTS - Narrative (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 2,196	$ 4,775

BALANCE SHEET COMPONENTS - Sche

BALANCE SHEET COMPONENTS - Schedule of accounts receivable, net (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounts receivable	$ 48		$ 119
Allowance for uncollectible accounts	(4)	$ (4)	(6)	$ (12)	$ 0	$ 0
Accounts receivable, net	$ 44		$ 113

BALANCE SHEET COMPONENTS - Sc_2

BALANCE SHEET COMPONENTS - Schedule of allowance for uncollectible accounts (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance as of beginning of period	$ 4	$ 0	$ 6	$ 0
Increase in provision	0	12	0	12
Amounts written off, less recoveries	0	0	(2)	0
Balance as of end of period	$ 4	$ 12	$ 4	$ 12

BALANCE SHEET COMPONENTS - Sc_3

BALANCE SHEET COMPONENTS - Schedule of inventory, net (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 729		$ 772
Finished goods	54		99
Total inventory	783		871
Less: reserve for obsolescence	(18)	$ (18)	(18)	$ (22)	$ (26)	$ (29)
Inventory, net	$ 765		$ 853

BALANCE SHEET COMPONENTS - Sc_4

BALANCE SHEET COMPONENTS - Schedule of activity in reserve for obsolescence (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Inventory, Valuation Reserves [Roll Forward]
Balance as of beginning of period	$ 18	$ 26	$ 18	$ 29
Increase in reserve	0	0	0	0
Amounts relieved	0	(4)	0	(7)
Balance as of end of period	$ 18	$ 22	$ 18	$ 22

BALANCE SHEET COMPONENTS - Sc_5

BALANCE SHEET COMPONENTS - Schedule of prepaid expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Professional services	$ 107	$ 41
Insurance	97	61
Software licenses	94	157
Other	14	6
Patents	10	39
Marketing programs and conferences	8	74
Prepaid expenses	$ 330	$ 378

BALANCE SHEET COMPONENTS - Sc_6

BALANCE SHEET COMPONENTS - Schedule of property and equipment, net (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Accumulated depreciation and amortization	$ (2,353)	$ (2,283)
Property and equipment, net	245	294
Depreciable Property, Plant and Equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,586	2,572
Property and equipment, net	233	289
Research and development equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,569	1,558
Office and computer equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	803	800
Autos
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	54	54
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	41	41
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	119	119
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 12	$ 5

BALANCE SHEET COMPONENTS - Sc_7

BALANCE SHEET COMPONENTS - Schedule of accrued expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Compensation, severance and related benefits	$ 468	$ 497
Legal services	138	36
Product warranty	15	18
Personal property and franchise tax	0	6
Other	0	3
Total accrued expenses	$ 621	$ 560

LEASES - Schedule of lease cost

LEASES - Schedule of lease cost (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Leases [Abstract]
Operating lease cost	$ 55	$ 56	$ 111	$ 112
Finance lease cost:
Amortization of right-of-use asset	0	11	0	27
Interest on lease liability	0	0	0	1
Total finance lease cost	$ 0	$ 11	$ 0	$ 28

LEASES - Schedule of maturities

LEASES - Schedule of maturities of operating leases liabilities (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Leases [Abstract]
2023	$ 99
2024	186
Total operating lease payments	285
Less imputed interest	(14)
Total operating lease liabilities	$ 271

STOCK-BASED COMPENSATION - Narr

STOCK-BASED COMPENSATION - Narrative (Details) - 2018 Equity Incentive Plan - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2018	Jun. 26, 2023
Stock-Based Compensation (Details) [Line Items]
Shares authorized (in shares)			848,614
Common stock, available for issuance (in shares)	465,580
Unrecognized compensation cost	$ 469
Stock Options
Stock-Based Compensation (Details) [Line Items]
Options, term		5 years
Weighted average grant date fair value (in dollars per share)	$ 1.24
Unrecognized compensation cost, period of recognition	1 year 7 months 6 days
Minimum | Stock Options
Stock-Based Compensation (Details) [Line Items]
Options, vesting period		12 months
Maximum | Stock Options
Stock-Based Compensation (Details) [Line Items]
Options, vesting period		36 months

STOCK-BASED COMPENSATION - Sche

STOCK-BASED COMPENSATION - Schedule of stock option activity (Details) - $ / shares	3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2023	Dec. 31, 2022
Number of Options
Beginning Balance (in shares)	280,448	280,810	280,810
Granted (in shares)	199,421		199,421
Exercised (in shares)	0		0
Forfeited (in shares)	(107)		(433)
Expired (in shares)	(336)		(372)
Ending Balance (in shares)	479,426	280,448	479,426	280,810
Exercisable (in shares)	139,583		139,583
Weighted Average Exercise Price Per Share
Beginning Balance (in dollars per share)	$ 17.11	$ 17	$ 17
Granted (in dollars per share)	1.25		1.25
Exercised (in dollars per share)	0		0
Forfeited (in dollars per share)	39.64		119.46
Expired (in dollars per share)	118.25		680.87
Ending Balance (in dollars per share)	10.01	$ 17.11	10.01	$ 17
Exercisable (in dollars per share)	$ 29.16		$ 29.16
Weighted Average Remaining Contractual Term (years)
Outstanding	4 years 6 months	4 years 4 months 24 days	4 years 6 months	3 years 10 months 24 days
Granted	5 years		5 years
Exercisable			3 years 9 months 18 days
Stock Options, Inducement Awards
Number of Options
Ending Balance (in shares)	99,000		99,000

STOCK-BASED COMPENSATION - Sc_2

STOCK-BASED COMPENSATION - Schedule of f value option assumptions (Details) - 2018 Equity Incentive Plan - Stock Options	6 Months Ended
	Jun. 30, 2023
Stock-Based Compensation (Details) [Line Items]
Expected volatility	128%
Expected dividend yield	0%
Expected term (in years)	5 years
Risk-free interest rate	5.30%

STOCK-BASED COMPENSATION - Sc_3

STOCK-BASED COMPENSATION - Schedule of restricted stock unit activity (Details) - Restricted Stock Units	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Number of Units
Beginning Balance (in shares) | shares	18,799
Granted (in shares) | shares	0
Vested (in shares) | shares	(18,799)
Forfeited (in shares) | shares	0
Ending Balance (in shares) | shares	0
Weighted Average Grant-Date Fair Value Per Unit
Beginning Balance (in dollars per share) | $ / shares	$ 2.71
Granted (in dollars per share) | $ / shares	0
Vested (in dollars per share) | $ / shares	2.71
Forfeited (in dollars per share) | $ / shares	0
Ending Balance (in dollars per share) | $ / shares	$ 0

STOCK-BASED COMPENSATION - Sc_4

STOCK-BASED COMPENSATION - Schedule of stock-based compensation expense (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Stock-Based Compensation (Details) [Line Items]
Total stock-based compensation expense	$ 170		$ 206		$ 336	$ 430
Issuance of common stock for service		$ 100	1	$ 3
Research and development
Stock-Based Compensation (Details) [Line Items]
Total stock-based compensation expense	5		3		9	4
Selling, general and administrative
Stock-Based Compensation (Details) [Line Items]
Total stock-based compensation expense	165		$ 203		327	$ 426
Issuance of common stock for service	$ 56				$ 56

STOCKHOLDERS' EQUITY - Activity

STOCKHOLDERS' EQUITY - Activity in stockholders' equity (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance (in shares)		809,648			809,648
Beginning Balance	$ 3,497	$ 5,279	$ 7,927	$ 10,035	$ 5,279	$ 10,035
Stock-based compensation	113	166	205	221
Issuance of common stock upon exercise of warrants		0
Issuance of common stock for service (in shares)					54,466
Issuance of common stock for service		100	1	3
Issuance of shares pursuant to the vesting of restricted stock units, net of shares withheld for taxes (in shares)					13,225
Issuance of shares pursuant to the vesting of restricted stock units, net of shares withheld for taxes		(11)
Issuance of common stock, net of issuance costs	1,210
Net loss	$ (1,993)	(2,037)	(2,569)	(2,332)	$ (4,030)	(4,901)
Ending Balance (in shares)	2,964,485				2,964,485
Ending Balance	$ 2,827	$ 3,497	$ 5,564	$ 7,927	$ 2,827	$ 5,564
Common Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance (in shares)	2,107,339	809,648	610,614	610,364	809,648	610,364
Beginning Balance	$ 2	$ 1	$ 1	$ 1	$ 1	$ 1
Issuance of common stock upon exercise of warrants (in shares)		1,230,000
Issuance of common stock upon exercise of warrants		$ 1
Issuance of common stock for service (in shares)		54,466	34	250
Issuance of shares pursuant to the vesting of restricted stock units, net of shares withheld for taxes (in shares)		13,225
Issuance of common stock, net of issuance costs (in shares)	857,146
Issuance of common stock, net of issuance costs	$ 1
Ending Balance (in shares)	2,964,485	2,107,339	610,648	610,614	2,964,485	610,648
Ending Balance	$ 3	$ 2	$ 1	$ 1	$ 3	$ 1
Additional Paid-In Capital
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	127,735	127,481	122,766	122,542	127,481	122,542
Stock-based compensation	113	166	205	221
Issuance of common stock upon exercise of warrants		(1)
Issuance of common stock for service		100	1	3
Issuance of shares pursuant to the vesting of restricted stock units, net of shares withheld for taxes		(11)
Issuance of common stock, net of issuance costs	1,209
Ending Balance	129,057	127,735	122,972	122,766	129,057	122,972
Accumulated Deficit
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(124,240)	(122,203)	(114,840)	(112,508)	(122,203)	(112,508)
Net loss	(1,993)	(2,037)	(2,569)	(2,332)
Ending Balance	$ (126,233)	$ (124,240)	$ (117,409)	$ (114,840)	$ (126,233)	$ (117,409)

STOCKHOLDERS' EQUITY - Narrativ

STOCKHOLDERS' EQUITY - Narrative (Details) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares
Stockholders’ Equity [Line Items]
Exercised (in dollars per share) | $ / shares	$ 3.50
Issuance of common stock for service (in shares)	54,466
Issuance of shares pursuant to the vesting of restricted stock units, net of shares withheld for taxes (in shares)	13,225
PreFunded Warrants, Issued in November 2022, Common Stock, Registered Direct Offering
Stockholders’ Equity [Line Items]
Issuance of common stock upon exercise of warrants (in shares)	1,230,000
Exercised (in dollars per share) | $ / shares	$ 3.50
Series C, Registered Direct Offering
Stockholders’ Equity [Line Items]
Common stock sold (in shares)	857,146
Common stock sold, price per share (in dollars per share) | $ / shares	$ 1.75
Common stock sold, gross proceeds | $	$ 1,500
Stock issuance costs | $	$ 290

COMMON STOCK WARRANTS - Schedul

COMMON STOCK WARRANTS - Schedule of common stock warrant activity for the period (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Shares
Beginning Balance (in shares)	4,414,810
Issued (in shares)	921,432
Exercised (in shares)	(1,230,000)
Expired (in shares)	(2,835)
Ending Balance (in shares)	4,103,407	4,414,810
Weighted Average Exercise Price Per Share
Beginning Balance (in dollars per share)	$ 6.58
Issued (in dollars per share)	1.66
Exercised (in dollars per share)	3.50
Expired (in dollars per share)	728
Ending Balance (in dollars per share)	$ 5.91	$ 6.58
Weighted Average Remaining Contractual Term (years)
Outstanding (in years)	3 years 2 months 12 days	3 years
Issued (in years)	5 years 3 months 18 days

COMMON STOCK WARRANTS - Narrati

COMMON STOCK WARRANTS - Narrative (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares year shares	Dec. 31, 2022 $ / shares
Class of Warrant or Right [Line Items]
Exercise price (in dollars per share)	$ 5.91	$ 6.58
Warrants, exercised (in shares) | shares	1,230,000
Warrants, exercised (in dollars per share)	$ 3.50
April 2023 Registered Direct Offering
Class of Warrant or Right [Line Items]
Exercise price (in dollars per share)	$ 1.62
Warrants, fair value | $	$ 1,100
April 2023 Registered Direct Offering | Measurement Input, Share Price
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	1.38
April 2023 Registered Direct Offering | Measurement Input, Price Volatility
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	1.64
April 2023 Registered Direct Offering | Measurement Input, Expected Term
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input | year	5.5
April 2023 Registered Direct Offering | Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0
April 2023 Registered Direct Offering | Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0.034
April 2023 Registered Direct Offering | Maximum
Class of Warrant or Right [Line Items]
Number of warrants (in shares) | shares	857,146
Common Stock, Warrants Issued to Placement Agent, April 2023, Registered Direct Offering
Class of Warrant or Right [Line Items]
Exercise price (in dollars per share)	$ 2.1875
Warrants, fair value | $	$ 82
Common Stock, Warrants Issued to Placement Agent, April 2023, Registered Direct Offering | Measurement Input, Share Price
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	1.38
Common Stock, Warrants Issued to Placement Agent, April 2023, Registered Direct Offering | Measurement Input, Price Volatility
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	1.65
Common Stock, Warrants Issued to Placement Agent, April 2023, Registered Direct Offering | Measurement Input, Expected Term
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input | year	5
Common Stock, Warrants Issued to Placement Agent, April 2023, Registered Direct Offering | Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0
Common Stock, Warrants Issued to Placement Agent, April 2023, Registered Direct Offering | Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0.035
Common Stock, Warrants Issued to Placement Agent, April 2023, Registered Direct Offering | Maximum
Class of Warrant or Right [Line Items]
Number of warrants (in shares) | shares	64,286
PreFunded Warrants, Issued in November 2022, Common Stock, Registered Direct Offering
Class of Warrant or Right [Line Items]
Warrants, exercised (in shares) | shares	1,230,000
Warrants, exercised (in dollars per share)	$ 3.50

LOSS PER SHARE -Schedule of out

LOSS PER SHARE -Schedule of outstanding potentially dilutive securities (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total (in shares)	10,171	0	242,127	0
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total (in shares)	0	0	166,661	0
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total (in shares)	10,171	0	75,466	0
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total (in shares)	0	0	0	0

CONTINGENCIES - Narrative (Deta

CONTINGENCIES - Narrative (Details) - Superior Court of the State of California, Kennan E. Kaedar Litigation - Pending Litigation	1 Months Ended
	Sep. 30, 2021 defendant	Jul. 31, 2020 USD ($)
Loss Contingencies [Line Items]
Number of defendants	10
Number of defendants, separately settled with plaintiff	2
Minimum
Loss Contingencies [Line Items]
Damages sought (in excess of) | $		$ 500,000

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details)	Jul. 21, 2023 USD ($)
Subsequent Event
Subsequent Event [Line Items]
Approved sale of stock, gross proceeds to be received (up to)	$ 7,500,000